u/Tiny_Split9436

Personally I’m very interested in maintenance research as I’m 65% on the way to it on my weight loss and have the open question what’s next apart from a lifetime of a maintenance dose, accept some regain, or being able to wean off and hold healthier habits.

The headlines are a bit “exercise pill” but ENV-308 has finished its first human trial in 88 healthy adults

It’s a once-daily pill based on Lac-Phe, a molecule the body produces during intense exercise.

No serious adverse events, no discontinuations or dose interruptions, and few GI problems were reported.

There’s no human weight-loss data yet. This was mainly a safety trial.

Enveda now plans to test it in people coming off GLP-1 treatment to see whether it can stop weight coming back.

In animal studies, the company says ENV-308 prevented weight regain after treatment stopped and preserved lean mass so back to my first point, quite interesting.

Original Lac-Phe paper:
https://www.nature.com/articles/s41586-022-04828-5

A lot has happened in the space over the last week.

August 18: Reports started coming in that multiple peptide-related Discord servers had been shut down. At least one individual server removal has been separately reported, although there’s no public confirmation from Discord that this is a coordinated reta-specific enforcement wave.

August 17: Two prominent peptide creators, Josh Holyfield and Trevor Bachmeyer, lost their YouTube channels. Holyfield says directly that YouTube took his channel down. Bachmeyer’s channel has also disappeared, although I haven’t seen a statement from him or YouTube explaining why.

August 12: Eli Lilly filed six new lawsuits against US businesses selling retatrutide — covering a medical spa, pharmacy and online peptide sellers.

That part is much bigger than six lawsuits.

Lilly says it has now:

• referred 200+ individuals and entities to the FDA, DOJ, state attorneys general, law enforcement and professional licensing boards
• reported 14,000+ websites, advertisements, social-media posts and product listings
• done so across 100+ countries
• explicitly called on social-media and e-commerce platforms, credit-card companies, payment processors, and shipping/logistics companies to cut off the infrastructure supporting grey-market retatrutide sales

The six defendants are Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide.

Taken together, this is starting to look less like a handful of lawsuits against individual vendors and more like pressure being applied across the wider ecosystem that allows the grey market to operate.

The important distinction is that Lilly’s legal action and requests to platforms are confirmed. The timing of the YouTube and Discord removals is also notable, but there’s currently no public evidence showing that Lilly directly requested those specific takedowns.

500 already. That went quickly 😊

It was only 7 days ago we hit 400, so that’s 25% growth in a week. It’s only a few weeks since 200 members milestone too.

Really good to see how much more active it’s getting. More questions, progress posts, people sharing what they’re finding and a lot more discussion in the comments.

I’m going to post a bit less and keep moderation pretty light. The main exception is sourcing, which will stay a hard rule. Any uncertainty if a post is OK then modmail to check.

Thanks to everyone posting, commenting and helping other people out.

1,000 next. I think we’ll get there sooner than I expected.

Tell the community a good news story!

1. Starting weight:

2. Current weight:

3: How many kgs/lbs lost (to save doing the math of 2-1 😉):

4: Timeframe (months):

5. Current dose:

6: Tips/tricks (exercise, no exercise, cardio, weights, calorie counting, steps etc):

Post your amazing stories and inspire!

Search results often lift a clinical-trial schedule and present it as though it tells an individual what they should take.

A trial protocol tells us what researchers tested using known study medication, eligibility screening, planned escalation, clinical monitoring, rules for interruptions and predefined outcomes.

The results are averages for randomised groups under those conditions. They are not personal prescribing instructions.

What doses do members (retas/g-3POs/triole-G Gang) here take and why?

TRIUMPH-2 source:

https://clinicaltrials.gov/study/NCT05929079

Looking for ideas. Have done teamLab and shopping….

It’s only 6 days since 300 was hit! It’s amazing to see how quickly it is taking off.

Thanks to all those contributing in the early days and helping shape the subreddit. I want it to become a positive, supportive community for current and future Reta users. I think it’s the tip of the iceberg so far, both for the sub and Reta itself!

Please feel free to post about experiences, questions, progress photos, symptoms. Replies are really appreciated too - especially for any Reta questions members have! It’s great to see the community helping each other.

One thing that’s been noticed is more sourcing posts that mods or Reddit have to remove. Please remember this is a sourcing free Reta sub.

One question is should the community members have a name? Retas…. Something else? Or just keep as members? I see some other subs have…

Retatrutide is often described as “GLP-3” or as three GLP-1 medicines in one. Neither description is really right. It is one molecule acting on GIP, GLP-1 and glucagon receptors.

The glucagon receptor is the additional part compared with tirzepatide, but online explanations often jump straight from that to claims about “burning fat” or “boosting metabolism” as though the clinical effect of each receptor can be cleanly separated.

What part of the glucagon story do you think people misunderstand most?

Background:

https://www.lilly.com/news/stories/what-to-know-about-retatrutide

I keep seeing both versions of this.

Some people say moving becomes easier quite quickly. Others say lower appetite, fatigue or a higher heart rate makes training harder, at least for a while.

What changed for you?

Energy, strength, endurance, heart rate, recovery, motivation, or nothing much?

Did it improve later?

We have had quite a few new members (50% more than a few weeks ago), so this is a simple introduction thread.

Are you following the clinical trials, already familiar with GLP-1 medicines, supporting somebody else, interested in the science, or just trying to work out what is real and what is hype?

What is the one question you came here hoping to answer?

There is no need to share anything personal that you would rather keep private.

In Seoul now with family. Thinking baseball may be fun this evening.

Looking online can’t see how to book in English, just Korean.

Can I just rock up at the Jamsil stadium and get tickets before the game? Any risk they sell out? Don’t care which ones too much want to give the kids the experience more.

Is it a good fun too for a family too (who don’t know much about baseball) ? Only ever been to see baseball at the Houston Astros once but so long ago.

here is a difference between being less hungry and simply not caring much about food. Some people say food noise disappears but they still enjoy meals. Others say they lose interest in food altogether, or eating starts to feel like a job. What has it been like for you, and did that change after the first few weeks?

TL;DR

• Retatrutide has now succeeded in three Phase 3 obesity trials.
• Lilly plans to submit it to the FDA in Q1 2027.
• Weight loss remained high in much harder-to-treat populations:
  • 28.3% in obesity without diabetes (TRIUMPH-1)
  • 20.8% in obesity with type 2 diabetes (TRIUMPH-2)
  • 22.6% in severe obesity with established cardiovascular disease (TRIUMPH-3)
• The direct comparison with tirzepatide (TRIUMPH-5) is still ongoing.
• The cardiovascular outcomes question will mainly be answered by the dedicated TRIUMPH-Outcomes study.

Lilly has announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two additional Phase 3 retatrutide trials.

The company now says it has the evidence needed to support regulatory submissions and plans to submit retatrutide to the FDA during Q1 2027. That is a planned filing date, not an approval date.

The Phase 3 programme so far

Retatrutide has now reported results from three major obesity trials.

Trial Population Average weight loss

TRIUMPH-1 Obesity without diabetes 28.3%

████████████████

TRIUMPH-2 Obesity or overweight with type 2 diabetes 20.8%

██████████

TRIUMPH-3 Severe obesity with established cardiovascular disease 22.6%

███████████

Weight loss remained above 20% even in people with type 2 diabetes and in people with severe obesity plus cardiovascular disease.

Historically, people with type 2 diabetes have generally lost less weight than people without diabetes in GLP-1 studies, making the 20.8% result particularly notable.

TRIUMPH-2

TRIUMPH-2 included 1,152 adults with obesity or overweight and type 2 diabetes.

After 80 weeks the efficacy-estimand results were:

• 4 mg: 12.7%
• 9 mg: 19.1%
• 12 mg: 20.8%
• Placebo: 4.0%

Average HbA1c started at 7.7%.

Average reductions were:

• 4 mg: 1.4%
• 9 mg: 1.6%
• 12 mg: 1.5%
• Placebo: 0.2%

These are efficacy-estimand results, estimating the effect if participants remained on treatment. Lilly has not yet released treatment-regimen analyses for these trials.

TRIUMPH-3

TRIUMPH-3 enrolled 1,949 adults with:

• BMI ≥35
• established cardiovascular disease

Average starting weight was 111.4 kg.

Average BMI was 40.4.

Weight loss at 80 weeks was:

• 9 mg: 21.6%
• 12 mg: 22.6%
• Placebo: 3.2%

Lilly also reported improvements in several cardiovascular risk markers including:

• triglycerides
• non-HDL cholesterol
• systolic blood pressure
• waist circumference
• high-sensitivity CRP

How does this compare with today's treatments?

There is an obvious temptation to compare the headline percentages.

For context:

Trial Drug Weight loss

TRIUMPH-1 Retatrutide 28.3%

SURMOUNT-1 Tirzepatide 22.5%

STEP-1 Semaglutide 14.9%

However these are different trials with different populations, different durations and different designs.

They should not be interpreted as proving one medicine is better than another.

That is exactly why TRIUMPH-5 is so important.

What still isn't answered?

Today's announcement is important, but several major questions remain.

Can retatrutide actually beat tirzepatide?

• TRIUMPH-5 should provide the first direct comparison.

How much additional weight loss is worth additional side effects?

• Average weight loss alone is unlikely to answer that.

Does retatrutide preserve muscle as well as fat?

• Body composition could become increasingly important as people remain on these medicines for years.

Does the glucagon receptor produce longer-lasting weight loss?

• One possibility is that retatrutide simply continues working after tirzepatide reaches a plateau.

Does it reduce cardiovascular events?

• Today's cardiovascular event numbers are reassuring but inconclusive.
• The dedicated 10,000-patient TRIUMPH-Outcomes trial is designed to answer that question.

What stood out?

Four findings deserve the most attention:

• Weight loss remained above 20% despite type 2 diabetes.
• Weight loss remained above 22% despite severe obesity and established cardiovascular disease.
• Lilly now plans FDA submission in Q1 2027.
• The biggest remaining unanswered question is still the direct comparison with tirzepatide.

Today's announcement makes the overall Phase 3 programme look increasingly consistent.

The next major milestone is likely to be TRIUMPH-5, because it should finally tell us whether retatrutide's apparent advantage over tirzepatide survives a direct head-to-head comparison under the same trial conditions.

Hello,

I hope this post is OK for this community. I want to ask for specific advice I haven’t been able to find here or online.

My son (13) is a keen pokemon card collector and has been playing more recently but has a good understanding of the rules and how to play.

In a few weeks we are going to Japan and I’ve just realised the Pokemon Cafe needed to be booked at the start of July. He wants to go to play pokemon though, not for a themed meal so I’m wondering if was right anyway.

I’m looking at Pokémon card lounge shibuya and it that is more appropriate. It seems he can take his own deck or borrow a deck (if he doesn’t want to travel with his). The questions I have are:

1. If we book, can he be paired with other players to battle? I don’t play so he won’t be arriving with someone to play against.
2. Can he play with an English language deck or does it need to be in Japanese?
3. Is language going to be a blocker to him playing or being paired with another player?

If anyone has any first hand experience it would be fantastic to hear.

The official materials make it sound very player friendly but I don’t know the answer to if it’ll work or we rock up and he won’t be able to actually have a game.

Thank you!!🙏